Playback speed
10 seconds
ASH 2022 Results From the Phase 1/2 BRUIN Study: Safety & Tolerability of Pirtobrutinib Monotherapy in Patients With B-Cell Malignancies Who Were Previously Intolerant to a Covalent BTKi
By
ASH 2022 Conference Coverage
FEATURING
Nirav Shah
By
ASH 2022 Conference Coverage
FEATURING
Nirav Shah
336 views
December 21, 2022
Login to view comments.
Click here to Login